GlassScriptPhysician profile
Michelle L Sapp
NPI 1619931136
$8,214.01
in general payments reported to CMS, 2019-2025
36 companies · $2,357 in 2025
The $2,357 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,867 · 2022: $996 · 2023: $935 · 2024: $2,058 · 2025: $2,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,006 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $225 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,006.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $225.00 |
| Education | $119.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $718.89 | 2021-2025 | Cresemba |
| Janssen Biotech, INC. | $717.79 | 2021-2025 | Carvykti, Rybrevant, Darzalex |
| Adaptive Biotechnologies Corporation | $700.38 | 2022-2025 | Clonoseq |
| Sanofi-Aventis U.S. LLC | $599.21 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $500.96 | 2021-2025 | Calquence |
| E.R. Squibb & Sons, L.L.C. | $476.33 | 2022-2025 | Abecma |
| Legend Biotech USA INC. | $442.33 | 2024-2025 | Carvykti |
| Celgene Corporation | $436.87 | 2021-2023 | Pomalyst |
| Beigene USA, INC. | $399.93 | 2024-2025 | Brukinsa |
| Melinta Therapeutics, LLC | $391.20 | 2024-2025 | Rezzayo |
| Incyte Corporation | $383.11 | 2021-2025 | Niktimvo, Jakafi, Niktimvo |
| Novartis Pharmaceuticals Corporation | $278.40 | 2021-2024 | |
| Seagen INC. | $184.14 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $161.23 | 2021-2023 | |
| Lantheus Medical Imaging, INC. | $152.40 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $143.18 | 2025 | Qinlock |
| Alexion Pharmaceuticals, INC. | $137.56 | 2025 | Ultomiris |
| Exelixis INC. | $134.94 | 2021 | |
| Johnson & Johnson Health Care Systems INC. | $134.40 | 2024 | Carvykti |
| Beone Medicines USA, INC. | $130.50 | 2025 | Brukinsa |
| Janssen Scientific Affairs, LLC | $130.00 | 2025 | Carvykti |
| Genmab U.S., INC. | $124.99 | 2025 | Epkinly |
| Genzyme Corporation | $124.89 | 2021 | |
| Amgen INC. | $113.29 | 2021 | |
| Stemline Therapeutics INC. | $110.93 | 2023-2024 | Elzonris |
| Foundation Medicine, INC. | $107.79 | 2021 | |
| Merck Sharp & Dohme LLC | $102.19 | 2023-2025 | Prevymis, Zerbaxa, Dificid |
| Dova Pharmaceuticals | $23.83 | 2021 | |
| Sobi, INC | $23.55 | 2025 | |
| Mayne Pharma Commercial LLC | $22.57 | 2021 | |
| Pfizer INC. | $21.29 | 2025 | |
| Caris Mpi, INC. | $19.04 | 2025 | Mi Cancer Seek |
| Daiichi Sankyo INC. | $17.24 | 2023 | Injectafer |
| Blueprint Medicines Corporation | $16.51 | 2025 | Ayvakit |
| Lilly USA, LLC | $16.26 | 2024 | Jaypirca |
| Janssen Pharmaceuticals, INC | $15.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Sapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.